Drugs.com - Clinical Trials

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

SAN CARLOS, Calif.--(BUSINESS WIRE) April 3, 2025 -- BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical...

May 12, 2025 - 09:53
 0
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
SAN CARLOS, Calif.--(BUSINESS WIRE) April 3, 2025 -- BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical...
Read More

Tags:

Previous Article

Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alz...

Next Article

Rilzabrutinib Granted Orphan Drug Designation in the US for Two Rare Diseases wi...

Related Posts

Repurposing Blood Pressure Drug Reserpine May Prevent Vision Loss in Inherited Blinding Diseases

Repurposing Blood Pressure Drug Reserpine May Prevent V...

May 12, 2025  0

Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis

Genentech’s Fenebrutinib Maintains Near-Complete Suppre...

May 31, 2025  0

Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Presented New Data From Pivotal Phase 3 IMPALA-2...

May 26, 2025  0